Table 2.
Rates of microbiological resistance.
| Antimicrobial Resistance | Comparisons by Semester (S) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Second S 2016 vs. Second S 2017 | Second S 2016 vs. Second S 2019 | Second S 2016 vs. First S 2022 | |||||||||||||
| % (n/N) Pre- Intervention Resistance |
% (n/N) Post- Intervention Resistance |
OR CI 95% |
p | % (n/N) Pre- Intervention Resistance |
% (n/N) Post- Intervention Resistance |
OR CI 95% | p | Prevented Rate (%) | % (n/N) Pre- Intervention Resistance |
% (n/N) Post- Intervention Resistance |
OR CI 95% | p | Prevented Rate (%) | ||
| E. coli | ESBL-producing | 10.73 (138/1285) |
7.69 (96/1248) |
0.68 (0.52–0.90) |
0.007 | 10.73 (138/1285) |
7.11 (83/1167) |
0.63 (0.47–0.84) |
<0.001 | 33.8 (14.1–48.5) |
10.73 (138/1285) |
6.13 (72/1174) |
0.54 (0.40–0.73) |
<0.001 | 45.7 (27.8–59.1) |
| Ciprofloxacin | 36.89 (474/1285) |
31.81 (397/1248) |
0.79 (0.67–0.94) |
0.004 | 36.89 (474/1285) |
21.67 (253/1167) |
0.47 (0.39–0.56) |
<0.001 | 41.2 (33.0–48.4) |
36.89 (474/1285) |
17.46 (205/1174) |
0.36 (0.29–0.43) |
<0.001 | 52.7 (45.3–59.0) |
|
| Co-amoxiclav | 20.46 (263/1285) |
18.72 (233/1248) |
0.89 (0.73–1.09) |
NS | 20.46 (263/1285) |
13.36 (156/1167) |
0.59 (0.48–0.74) |
<0.001 | 34.7 (21.7–45.5) |
20.46 (263/1285) |
13.71 (161/1174) |
0.61 (0.49–0.76) |
<0.001 | 33.0 (19.8–44.0) |
|
| K. pneumoniae | ESBL-producing | 9.62 (23/239) |
13.95 (30/215) |
1.52 (0.88–2.71) |
NS | 9.62 (23/239) |
14.17 (37/1167) |
1.05 (0.89–2.69) |
NS | NA | 9.62 (23/239) |
8.80 (22/250) |
0.90 (0.49–1.67) |
NS | NA |
| Ciprofloxacin | 14.64 (35/239) |
17.67 (38/215) |
1.25 (0.75–2.06) |
NS | 14.64 (35/239) |
19.92 (52/1167) |
1.45 (0.90–2.32) |
NS | NA | 14.64 (35/239) |
10.40 (26/250) |
0.67 (0.39–1.16) |
NS | NA | |
| Co-amoxiclav | 14.64 (35/239) |
18.13 (39/215) |
1.29 (0.78–2.12) |
NS | 14.64 (35/239) |
15.70 (41/1167) |
1.08 (0.66–1.77) |
NS | NA | 14.64 (35/239) |
10.00 (25/250) |
0.64 (0.37–1.11) |
NS | NA | |
(n/N); n; total positive antibiograms, N; total antibiograms, ESBL; extended-spectrum β-lactamase. Co-amoxiclav; amoxicillin–clavulanic acid; NS; not significant. NA; not applicable.